Isotope Technology

ITM Isotope Technologies Munich is a leading privately held radiopharmaceutical company dedicated to developing, producing, and globally supplying high-quality diagnostic and therapeutic radionuclides and radiopharmaceuticals for cancer treatment. The company operates a robust pipeline of targeted radionuclide therapies, most notably ITM-11 (n.c.a. 177Lu-edotreotide), which is currently in Phase 3 clinical trials for gastroenteropancreatic neuroendocrine tumors. Beyond its own drug development, ITM is a critical global supplier of medical radioisotopes, including no-carrier-added Lutetium-177 and Actinium-225, supporting both clinical research and commercial healthcare markets. The company maintains large-scale GMP manufacturing capabilities and collaborates extensively with major pharmaceutical players and academic institutions to advance the field of precision oncology.